Psoriasis is a chronic illness with long coarse duration wich can affects all age groups and both sexes are equally affected, as other autoimmune disease it characterized by over production of many inflammatory cytokines including IL-6.
Clinically the disease characterized by well demarcated erythematous silvery plaques on affected areas. Psoriasis vulgaris is the most common type of psoriasis which account for 85-95% of all cases.
The disease has no permanent cure, but treatments lines were present to relief the symptoms of disease. There are several adopted modes of treatments available including, topical, UVR, systemic including oral and injectable treatments according to the disease severities.
Methotrexate and Adalimumab are most common systemic treatment in the management of plaque psoriasis with the good clinical response.
AIM OF WORK:
The aim of this study was to assess serum level of IL-6 before and after methotrexate treatment and compared to its level before and after treatment with adalimumab.